AI is designing therapies faster than factories can make them. Multiply Labs’ bet is that robotic clusters—owned by the drugmaker, not run as a CDMO service—can close that gap.
On 7 October 2026, Multiply Labs announced a $75 million Series B, bringing total capital raised to over $100 million since its 2016 founding as a Y Combinator startup. The round was led by Dr Patrick Soon-Shiong with NantWorks, with new investors including AstraZeneca, Lingotto, Teradyne, and Strange Ventures, and returning backers including Casdin Capital, Lux Capital, Fifty Years, Ora Global, and Founders Fund, among others. Dr Ileana Pirozzi of Lingotto Innovation joined the board. [1]
This is a company press release carried on BioSpace / Business Wire. Performance figures below are company claims.
What the robots supposedly do
Multiply Labs builds robotic clusters that integrate with a company’s existing instruments and processes—without requiring a new facility or changes to already-validated practices, the company says. Each cluster automates the timed, repetitive steps of biologics manufacturing within an enclosed, GMP-compliant system. [1]
The release claims a 74% reduction in cost per dose and up to 100 times more throughput than manual manufacturing. The system is described as autonomous rather than merely automated—learning, adapting, and running continuously to remove the manual handoffs between process steps where contamination risk is highest. A single contamination event, the company notes in framing, can cost millions and delay access to medicine. Those metrics and risk framings are company-reported, not independently audited here. [1]
Owned by the pharma company, not outsourced
Beginning with cell and gene therapy and expanding to advanced biologics including antibodies, viral vectors, and mRNA, the platform is owned and operated by pharmaceutical and biologics companies rather than sold as an outsourced manufacturing service—keeping production, data, and supply chain fully in-house, per the company. That ownership model is part of what the release says drew this investor base. [1]
CEO and co-founder Fred Parietti framed robotics as the only way to deliver these therapies to patients at scale, arguing AI is designing more therapies than the industry can manufacture. Capital will expand manufacturing capacity, accelerate the product roadmap, and scale engineering, regulatory, and commercial teams for the transition from clinical-stage deployments to commercial-scale production. [1]
Why the investor mix is notable (still not advice)
Having AstraZeneca and Teradyne alongside specialist biotech and deep-tech funds signals both pharma demand-side interest and industrial-automation capital—consistent with a physical-AI manufacturing thesis. It is still a fundraising announcement, not proof of commercial-scale outcomes. This is not investment advice. [1]
What we don’t know
- Named commercial customers and how many clusters are in live GMP production.
- Independent verification of the 74% cost and 100× throughput claims.
- Regulatory milestones beyond the company’s GMP-compliance framing.
- How quickly clinical-stage deployments convert to commercial-scale runs.
What this does not prove
Raising $75 million does not prove that robotic clusters already match manual quality at commercial volumes for every modality listed, or that contamination rates have fallen by a published independent amount. It proves Multiply Labs has capital to try. [1]
The Bottom Line
Multiply Labs has another $75 million—and more than $100 million total—to push robotic biologics manufacturing from clinical deployments toward commercial scale. The manufacturing bottleneck is real; the percentage claims remain company-reported until outsiders can check them. This is not investment advice.
Sources
- Multiply Labs via BioSpace / Business Wire (company release) — 7 October 2026 — https://www.biospace.com/press-releases/multiply-labs-raises-75-million-series-b-to-close-the-gap-between-drug-discovery-and-drug-manufacturing
